The vaccine against Covid-19 from the American laboratory Novavax, based on classic technology, will become the fifth to be available in France after the green light from the High Authority for Health (HAS) on Friday.
This vaccine and that of Janssen may in some cases be “a useful alternative“for people reluctant to be injected with messenger RNA vaccines from Pfizer and Moderna, judge HAS.
Even if four vaccines were previously authorized in France, those of Pfizer and Moderna are, in fact, almost exclusively used. They are based on a novel technology, messenger RNA.
►►► Read also : Is Covid-19 becoming an endemic disease? The explanations of Professor Nathan Clumeck (ULB)
The other two, those of AstraZeneca and Janssen, are redirected to poor countries via the international Covax program.
The first deliveries of the Novavax vaccine (marketed under the name Nuvaxovid) should take place in early February, the Ministry of Health said this week, pending the opinion of the HAS. The European Union gave the green light on December 21 to this vaccine based on the same technology as that of whooping cough.
Responsible for defining the vaccine policy of France, the HAS believes in its new opinion that we must “privilege“mRNA vaccines for the first injections as well as for the booster, because of their high efficacy.
However, she considers that Novavax and Janssen “represent an additional option“for people who”do not wish or cannot receive“of mRNA vaccines.